Erratum: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial (JAMA - Journal of the American Medical Association (2017) 318:23 (2306-2316) DOI: 10.1001/jama.2017.18718);Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 23, 2017, Pages 2306-2316

  Stupp, Roger ^a,b,c   Taillibert, Sophie ^b,d   Kanner, Andrew ^e   Read, William ^f,g   Steinberg, David M ^h   Lhermitte, Benoit ^b   Toms, Steven ⁱ   Idbaih, Ahmed ^d   Ahluwalia, Manmeet S ^j   Fink, Karen ^k   Di Meco, Francesco ^l   Lieberman, Frank ^m,n   Zhu, Jay Jiguang ^o,p   Stragliotto, Giuseppe ^q   Tran, David D ^r   Brem, Steven ^s,t   Hottinger, Andreas F ^b   Kirson, Eilon D ^u   Lavy Shahaf, Gitit ^u   Weinberg, Uri ^u   Kim, Chae Yong ^v   Paek, Sun Ha ^w   Nicholas, Garth ^x   Burna, Jordi ^y   Hirte, Hal ^z   Weller, Michael ^c   Palti, Yoram ^u   Hegi, Monika E ^b   Ram, Zvi ^e   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d SORBONNE UNIVERSITÉ   (France)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g EMORY UNIVERSITY   (United States)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ GEISINGER HEALTH SYSTEM   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l DEPARTMENT OF NEUROSURGERY   (Italy)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ University of Pittsburgh Medical Center ^*  (United States)

^o UNIVERSITY OF TEXAS   (United States)

^p TUFTS MEDICAL CENTER   (United States)

^q KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^r BARNES JEWISH HOSPITAL   (United States)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u Novocure GmbH   (Israel)

^v Seoul National University Bundang Hospital   (South Korea)

^w Seoul National University   (South Korea)

^x OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^y HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^z JURAVINSKI CANCER CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; ANOREXIA; ANXIETY; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; CANCER GROWTH; CANCER SURGERY; CHEMORADIOTHERAPY; CONFUSION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEHYDRATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTRIC FIELD; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GAIT DISORDER; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; INFORMED CONSENT; INJURY; INSOMNIA; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SKIN IRRITATION; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ELECTROTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MITOSIS; SURVIVAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; ELECTRIC STIMULATION THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MITOSIS; SURVIVAL ANALYSIS;

EID: 85040033962     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.3431     Document Type: Erratum

References (26)

1. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl 5):v1-v75.
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007; 25(26):4127-4136.
3. Stupp R, Hegi ME, Gorlia T, et al; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
4. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370 (8):709-722.
5. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370 (8):699-708.
6. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
7. Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
8. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
9. Westphal M, Heese O, Steinbach JP, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51(4):522-532.
10. Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152-10157.
11. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046.
12. Kirson ED, Schneiderman RS, Dbalý V, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.
13. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
14. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543.
15. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2): 97-109.
16. Ganiere V, Christen G, Bally F, et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol. 2006;3(6):339-343.
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
18. Taphoorn MJ, Claassens L, Aaronson NK, et al; EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033-1040.
19. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
20. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10(4):332-337.
21. Hegi ME, Janzer RC, Lambiv WL, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 2012;123(6):841-852.
22. Coulibaly B, Nanni I, Quilichini B, et al. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. Hum Pathol. 2010;41(6):815-823.
23. DeMets DL, Lan G. The alpha spending function approach to interim data analyses. Cancer Treat Res. 1995;75:1-27.
24. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994; 13(13-14):1341-1352.
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
26. Weller M, Butowski N, Tran DD, et al; ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373-1385.